'Pfizer at a Pivotal Moment in Its History and the Entire Pharmaceutical Industry Needs to Pay Attention' Says Visiongain.SAN FRANCISCO San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden & LONDON -- Pfizer, the world's first druggernaut, has sales of over $52 billion and profits of $14 billion and showed 17% growth from 2003 to 2004, far above the industry average. However, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the latest visiongain report specifically focussed on the drug company, the next five years may not be as positive. Pfizer owns the patents to some of the world's top drugs, including ten blockbusters (drugs with over $1bn annual sales revenue), but the company is about to lose the patent protection to a number of key products, and consequently suffer significant income loss in a very short space of time. Lipitor, the world's best-selling best·sell·er also best seller n. A product, such as a book, that is among those sold in the largest numbers. best drug, will have patent protection until at least 2009, but is producing such high revenues that the generic companies are itching itching or pruritus Stimulation of nerve endings in the skin, usually incited by histamine, that evokes a desire to scratch. It is often transient and easily relieved. Pathological itching with skin changes usually signals dermatologic disease. to gain some of the market share. Pfizer has already lost one patent court battle for Lipitor, admittedly in the relatively insignificant Austrian market. Even the market strength of Viagra is wilting wilting dehydration of plants to the point where the leaves lose their turgor and hang limply. Can happen in living plants which later return to normal, or to cut plants before they are fed out. Thought to be a factor in increasing toxicity. as competitors take its market share. "Although recent Q3 results from Pfizer were not as positive as many in the industry were expecting, they were not a surprise," says Tristan Heath pharmaceutical market analyst at visiongain. "Whilst Pfizer have dominated the pharmaceutical industry in recent years, the Years, The the seven decades of Eleanor Pargiter’s life. [Br. Lit.: Benét, 1109] See : Time latest downturn in sales and future profit warnings from Pfizer were predicted by visiongain in our latest report - Pfizer, Current Challenges and Future Difficulties, 2005-2010." Pfizer has not given up, and this year plans to spend a staggering $8 billion on research and development. However its search for the next blockbuster block·bust·er n. 1. Something, such as a film or book, that sustains widespread popularity and achieves enormous sales. 2. A high-explosive bomb used for demolition purposes. 3. is not an easy one and visiongain doubts whether Pfizer will rely on their research alone for continued success. The $60 billion Pharmacia merger propelled Pfizer to the top but was a mixed blessing mixed blessing Noun an event or situation with both advantages and disadvantages mixed blessing n it's a mixed blessing → tiene su lado bueno y su lado malo . Pfizer gained the rights to the painkilling blockbusters, Bextra and Celebrex, but these have suffered under the Vioxx scandal. Visiongain believes that Pfizer will look for other mergers to satisfy the demand for further growth. As health authorities, particularly in the US and EU, try to reduce their expenditure on drugs still further, this visiongain report explores the key issues for Pfizer and how it plans to remain the most influential drug company in the world today. Notes for editors: To receive your complimentary overview of - Pfizer, Current Challenges and Future Difficulties, 2005-2010 - Please send an email to Sara Peerun sara.peerun@visiongain.com, telephone Sara on +44 (0) 20 8767 6711 or visit www.visiongain.com. Please include your full name, title of publication, contact telephone number, email, and details of where you saw this release. Upon receipt of this information, an overview will be emailed to you. Background: Visiongain is one of the fastest growing and most innovative independent media companies in Europe today Europe Today is a daily radio news show on the BBC World Service about public affairs throughout Europe. It is presented by Audrey Carville at 17:00 GMT every weekday. External links
For information on visiongain, please visit www.visiongain.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion